Tick-Borne Encephalitis

Commercial Assays Not Specific Enough

Published in Virus Weekly, March 27th, 2001

by N.R. Saltmarsh, staff medical writer - A comparison of six commercial enzyme immunoassays (EIAs) for the detection of tick-borne encephalitis reveals a lack of accuracy due to cross-reaction with other members of the Flaviviridae.

M. Niedrig and colleagues set out to compare EIA specificity for tick-borne encephalitis virus (TBEV), a human flavivirus endemic in some parts of Europe and Asia. The EIAs typically are used to test for presence of the disease or the success of vaccination.

The researchers used six EIAs to test serum samples from 109 patients infected with TBEV and an additional 30 patients vaccinated against it, as well as serum...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Virus Weekly

Source: Virus Weekly (2001-03-27)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry